In this article, we will discuss Romiplostim (Mechanism of Action). So, let’s get started.
Mechanism of Action
Romiplostim increases platelet production through binding and activation of the TPO receptor, a mechanism analogous to
In clinical studies, treatment with Romiplostim resulted in dose-dependent increases in platelet counts. After a single subcutaneous dose of 1 to 10 mcg/kg Romiplostim in patients with chronic ITP, the peak platelet count was 1.3 to 14.9 times greater than the baseline platelet count over a 2- to 3-week period. The platelet counts were above 50 × 109/L for seven out of eight patients with chronic ITP who received six weekly doses of Romiplostim at 1 mcg/kg.